John Pinching - Profile and Journalist Details

Beats

Content

Total articles 1138

• Leqembi approved as first treatment to slow early Alzheimer’s progression

  By John Pinching Verified| PharmaTimes Verified The European Commission has granted marketing authorisation for Leqembi (lecanemab), making it the first therapy in the EU to slow the progression of early Alzheimer’s disease. Lecanemab is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer’s who are apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.

  By John Pinching Verified · PharmaTimes

  Apr. 16, 2025

• Pepaxti shows effectiveness in heavily pretreated multiple myeloma patients

  By John Pinching Verified| PharmaTimes Verified Real-world data from the University of Catania, Italy, suggest that Pepaxti, a treatment for relapsed, refractory multiple myeloma (RRMM), is effective and well tolerated in heavily pretreated patients. The retrospective analysis included eight triple-class refractory RRMM patients who had received a median of 3.5 prior lines of therapy. Some had high-risk features, including extramedullary disease, yet Pepaxti, combined with dexamethasone, achieved an overall response rate of 37.5%.

  By John Pinching Verified · PharmaTimes

  Apr. 16, 2025

• New data reinforce daratumumab as standard of care for multiple myeloma

  By John Pinching Verified| PharmaTimes Verified New data from Janssen-Cilag International NV suggest that subcutaneous DARZALEX (daratumumab) quadruplet therapy could offer a longer progression free survival for patients with newly diagnosed multiple myeloma. Findings were presented at the 6th European Myeloma Network meeting in Athens. Analysis based on the PERSEUS and CEPHEUS trials showed significant improvements in survival projections.

  By John Pinching Verified · PharmaTimes

  Apr. 15, 2025

As seen in

Company Info

PharmaTimes

PharmaTimes Media Ltd is a UK-based company specializing in pharmaceutical media. It offers a range of publications, including the leading pharmaceutical magazine in the UK, which is available in both print and digital formats. The magazine delivers independent and authoritative content, covering trends and issues in the pharmaceutical industry across the UK, Europe, and globally. In addition to its publications, PharmaTimes hosts competitions that allow industry professionals to demonstrate their skills in areas such as marketing, communications, and clinical research. These competitions are designed by independent experts and provide participants with real-life challenges and feedback. The company also conducts webinars and produces thought leadership content, focusing on critical topics in the pharmaceutical and healthcare sectors. With a circulation of over 23,000 industry professionals, including NHS healthcare professionals, PharmaTimes Media Ltd plays a vital role in facilitating discussions and engagement within the pharmaceutical landscape.